

医渡科技 5 月通讯 | 2023 年

Yidu Tech Events in May 2023

集团亮点

Business Update

医渡科技联合创始人、CEO 徐济铭出席 2023 数博会

Xu Jiming, co-founder and CEO of Yidu Tech, attended the 2023 China International Big Data Industry Expo

2023 中国国际大数据产业博览会在贵阳召开，医渡科技作为人工智能领域重点企业受邀参会，医渡科技联合创始人、CEO 徐济铭在会上发表《医疗智能，创赢未来》主题演讲，并参与了“人工智能与产业元宇宙”论坛关于“人工智能赋能生命科学-机遇与挑战”主题圆桌对话，分享了公司最新发展成果，还针对前沿技术趋势、行业发展机遇展开了深入分析、探讨。

The 2023 China International Big Data Industry Expo was held in Guiyang. Yidu Tech, a leading player in artificial intelligence, was invited to participate. Xu Jiming, co-founder and CEO of Yidu Tech, delivered a keynote speech entitled "Healthcare Intelligence: Embracing a Promising Future" at the forum. He also participated in the "Artificial Intelligence and the Metaverse of Industries" forum and took part in a roundtable discussion on the topic of "Artificial Intelligence Empowering Life Sciences: Opportunities and Challenges." During these engagements, Xu Jiming shared the company's latest developments and achievements, facilitating in-depth analysis and discussions on emerging technological trends and industry opportunities.

据媒体报道，贵州省委书记、省人大常委会主任徐麟等领导在谈及数字经济发展时多次提到医渡科技，对公司近年来在医疗智能领域取得的成绩予以认可。

Media reports indicate that Yidu Tech has garnered significant attention from prominent figures such as Xu Lin, the Secretary of the Guizhou Provincial Party Committee and the Chairman of the Standing Committee of the Provincial People's

Congress, as well as other leaders, during discussions on the development of the digital economy. These leaders have acknowledged the noteworthy accomplishments of Yidu Tech in the realm of healthcare intelligence over the past few years.



医渡科技两大重磅产品亮相 CHIMA2023

Yidu Tech's two flagship products debuted at CHIMA 2023

中国医院信息网络大会（CHIMA2023）在福州隆重召开，医渡科技旗下医渡云携两大重磅产品——「新一代数据中心 YiduEywa 2.0」和「新一代科研数据平台（全病种数据库平台）」亮相大会。

The 2023 Information Network Congress of China Hospital Association has been held in Fuzhou. Yidu Tech showcased two significant flagship products, the "New-generation Data Center YiduEywa 2.0" and the "Next-generation Research Data Platform (All-Disease Database Platform)" at the conference.



医渡科技旗下因数云出席国金证券中期策略会

CausaCloud, a subsidiary of Yidu Tech, has attended the Sinolink Securities Mid-Term Strategy Conference

国金证券携手安徽省政府在安徽合肥召开“迎客松产业高峰论坛”暨国金证券中期策略会，众多上市公司高管、专家围绕 AI+创新主线展开深入研讨。医渡科技旗下因数云副总裁郭潇宇受邀出席，并发表了《AI 助力多层次医疗保障》主题演讲，生动分析了 AI 技术对医疗行业的改变和价值，分享了医疗 AI 的最新趋势，以及 AI 在助力多层次医疗保障中的实践和成果。

In collaboration with the Anhui Provincial Government, Sinolink Securities organized The Pine Greeting Guests Industry Summit Forum and the Sinolink Securities Mid-Term Strategy Conference in Hefei, Anhui. Prominent executives from listed companies and experts engaged in extensive discussions focused on the theme of AI+ innovation. Yidu Tech's subsidiary, CausaCloud, had the privilege of having its Vice President, Guo Xiaoyu, invited to attend the event as a guest speaker. Guo Xiaoyu

delivered a keynote speech titled "AI Empowering Multilevel Healthcare Security." Guo Xiaoyu vividly analyzed the impact and value of AI technology in the healthcare industry, shared the latest trends in healthcare AI and highlighted the practical applications and achievements of AI in enhancing multilevel healthcare security.

医渡科技旗下 HLT 参与撰写的 4 篇学术论文入选 ISPOR 年会壁报交流

Selection of Four Academic Papers Co-Authored by Yidu Tech's Subsidiary, HLT, for Poster Presentation at the ISPOR Annual Conference

2023 年第 28 届国际药物经济学与结果研究学会（ISPOR）年会在美国召开。医渡科技旗下开心生活科技（HLT）参与撰写的 4 篇学术论文入选大会壁报交流，主题涉及“皮肤 T 细胞淋巴瘤患者经济负担和健康相关生活质量研究”、“中国医生用口服抗凝剂治疗房颤的处方模式和偏好调查”、“罕见病‘肝糖储积症’的医疗资源利用及成本分析及其并发症研究”。

The 28th Annual Meeting for 2023 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) was held in the United States. Four academic papers co-authored by HLT, a subsidiary of Yidu Tech, was selected for poster presentation at the conference. These papers delve into significant topics, including the economic burden and health-related quality of life for patients with cutaneous T-cell lymphoma, prescription patterns, preferences of Chinese physicians regarding oral anticoagulant treatment for atrial fibrillation, and medical resource utilization, cost analysis, and complications associated with the rare disease known as "glycogen storage disease".

HLT 助力《晚期乳腺癌患者疾病负担白皮书》发布

HLT contributes to the release of the "White Paper on Disease Burden in Advanced Breast Cancer Patients"

第三届中国肿瘤创新论坛在海南博鳌顺利召开，由琼海博鳌肿瘤创新研究院和医渡科技旗下开心生活科技（HLT）合作开展的《中国晚期 HR+HER2-乳腺癌患者疾病负担与生活质量调研白皮书》正式在大会发布。

The 3rd Chinese Cancer Innovation Forum was successfully held at the Boao Forum in Hainan. One of the highlights of the event was the official release of the "White Paper on Disease Burden and Quality of Life of Chinese Patients with Late-Period HR+/HER2- Breast Cancer." This white paper, jointly produced by the Qionghai Boao Cancer Innovation Research Institute and Happy Life Tech (HLT), a subsidiary of Yidu Tech, was unveiled during the conference.



HLT 出席第四届“高风险医疗器械法规与临床研究技术论坛”

HLT attended the 4th “High-Risk Medical Device Regulations and Clinical Research Technology Forum”

第四届“高风险医疗器械法规与临床研究技术论坛”上，医渡科技旗下开心生活科技（HLT）医疗器械临床运营负责人、高级总监杨苏受邀参会并做主题报告，分享医疗器械相关法规、医疗器械临床项目管理的全流程、远程智能临床试验（DCT）赋能器械研究的实践案例，探讨如何借助智能系统，推动临床研究高质、高效开展，实现降本增效。

During the 4th "High-Risk Medical Device Regulations and Clinical Research Technology Forum", Yang Su, the Clinical Operations Manager and Senior Director of

Happy Life Tech (HLT), a subsidiary of Yidu Tech, was invited to attend and deliver a presentation. Yang Su shared insights on medical device regulations, the end-to-end management of clinical projects for medical devices, and practical case studies on the application of decentralized clinical trials (DCT) in device research. The discussion focused on leveraging intelligent systems to promote high-quality and efficient clinical research, while achieving cost reduction and efficiency improvement.

HLT 出席第十一届中国医药决策科学峰会暨 CphMRA2023 年度工作会议

HLT attended the 11th China Pharmaceutical Decision Sciences Summit and CphMRA 2023 Annual Work Meeting

第十一届中国医药决策科学峰会暨 CphMRA2023 年度工作会议在武汉举办，医渡科技旗下开心生活科技（HLT）真实世界洞察与咨询业务部夏若冰、李岚、栾嵘受邀发表主题演讲，与行业分享细胞基因疗法商业化路径前瞻、「真实世界洞察+调研」双擎驱动商业决策，整合多源数据深度分析助力新产品上市精准决策。

The 11th China Pharmaceutical Decision Sciences Summit and CphMRA 2023 Annual Work Meeting were held in Wuhan. Xia Ruobing, Li Lan, and Luan Rong from the Real-World Insights and Consulting Division of Happy Life Tech (HLT), a subsidiary of Yidu Tech, were invited to deliver keynote speeches, sharing insights on the commercialization pathway of cell and gene therapies, the synergy of real-world insights and research to drive business decisions, and the integration of multi-source data for in-depth analysis to support precise decision-making in new product launches.

业务进展

Business Progress

“深圳惠民保”参保人数近 350 万，医渡科技旗下因数云担任主运营平台

The "Shenzhen Huimin Insurance " has a membership of nearly 3.5 million people, with CausaCloud, a subsidiary of Yidu Tech, functions as the main

operating platform

截至 6 月 6 日，原深圳“重疾险”升级版“深圳惠民保”已有近 350 万人参保。医渡科技旗下因数云作为“深圳惠民保”主运营平台方，为该项目提供多项综合服务，有力地保障了项目的落地和稳定运营。截至目前，医渡科技已中标参与了江苏、北京、天津、深圳等 4 省 12 市惠民保项目的开发和运营，以智能技术助力构建多层次医疗保障体系。

As of June 6th, the upgraded version of the original "Critical Illness Insurance" in Shenzhen, known as "Shenzhen Huimin Insurance," has attracted nearly 3.5 million insured individuals. As the main operation platform of "Shenzhen Huimin Insurance," CausaCloud, a subsidiary of Yidu Tech, provides a number of comprehensive services for the project, which effectively ensured the successful implementation and stable operation of the project. Up to now, Yidu Tech has won the bid to participate in the development and operation of Hui Min Insurance projects in 4 provinces and 12 cities, such as Jiangsu, Beijing, Tianjin and Shenzhen, helping to build a multi-level medical security system with intelligent technology.

医渡云中临床机构评价数据平台项目

YiduCloud Wins the Bid for Clinical Trial Institution Evaluation Data Platform

Project

医渡科技的附属公司医渡云（北京）技术有限公司中标“临床机构评价数据平台”建设项目。该全国性平台旨在提升临床机构能力和规范性，实现临床机构分层管理和智慧监管。

YiduCloud (Beijing) Technology Co., Ltd., an affiliated company of Yidu Tech, won the bid for the construction project of "Clinical Trial Institution Evaluation Data Platform." The project aims to improve the capability and standardization of clinical trial institutions and realize hierarchical management and intelligent supervision of clinical trial institutions.

医渡云承建的“国家眼部疾病临床医学研究中心大数据平台”正式发布

The "Big Data Platform of National Eye Disease Clinical Medicine Research Center" constructed by YiduCloud was officially released

由温州医科大学附属眼视光医院与医渡科技旗下医渡云携手建设的“国家眼部疾病临床医学研究中心大数据平台”在2023视觉健康创新发展国际论坛上正式发布。平台将支撑临床医学研究高质量开展，助力眼部疾病领域的科研提效、标准沉淀和创新探索。

The "Big Data Platform of National Eye Disease Clinical Medicine Research Center" jointly constructed by Eye Hospital of Wenzhou Medical University and YiduCloud, a subsidiary of Yidu Tech, was officially released at the 2023 International Forum on Innovation and Development of Visual Health. The platform will support the high-quality development of clinical medicine research, and assist the scientific research efficiency improvement, standard precipitation and innovative exploration in the field of eye diseases.



医渡云助力宁波大学附属第一医院建设临床医学数据平台并开展应用培训

YiduCloud helps the First Affiliated Hospital of Ningbo University to build Clinical Medical Data Platform and carry out application training

宁波大学附属第一医院“临床医学数据平台应用培训”会成功举办，该院信息科、数据中心以及临床科室等百余人积极参与，作为平台建设方，医渡云受邀参会并进行平台介绍和使用培训。目前，临床医学数据平台已基本建成，即将进入试运行阶段。平台的投入使用不仅可以帮助医生和科研人员对文本电子病历、数值检查检验等数据进行科学分析，还能帮助管理者实现精准分析和科学决策，提升效率和准确性，推动科研成果产出和转化。

The First Affiliated Hospital of Ningbo University successfully held the "Training on Application of Clinical Medical Data Platform." More than 100 people from the Information Department, Data Center and clinical departments of the hospital actively participated in the meeting. As the platform builder, YiduCloud was invited to attend the meeting and conduct platform introduction and training. At present, the clinical medical data platform has been basically completed and will soon enter the trial operation stage. The application of the platform can not only help doctors and researchers to scientifically analyze the data such as text electronic medical records and numerical examination and inspection, but also help managers realize accurate analysis and scientific decision-making, improve efficiency and accuracy, and promote the output and transformation of scientific research achievements.



医渡云中标某市辖区卫健委卫生信息系统运维和医疗机构运营监管分析项目

YiduCloud wins bid for Health Information System Maintenance and Operation Supervision Project of a certain district health committee in a city

为支撑该市辖区的医疗卫生日常工作，医渡云将助力开展卫生健康信息化系统的运维管理工作。同时，在该市辖区医疗大数据平台支撑基础上，助力构建医疗卫生机构运营监管分析体系，补充对区域医疗卫生机构运营监管分析的智能化监测。该项目预计明年建成。

In order to support the daily medical and healthcare work of the municipal district, YiduCloud will assist in carrying out the operation and maintenance management of the health information system. In addition, by utilizing the existing local medical big data platform, YiduCloud will assist in developing an operational supervision and analysis system for healthcare institutions, thereby enhancing intelligent monitoring of regional healthcare institution operations. The project is expected to be completed next year.

医渡云中标华东地区某三甲医院脓毒血症相关项目

YiduCloud has successfully secured the contract for a sepsis-related project in a tertiary hospital located in the East China region

医渡云将以脓毒血症专病库建设为重点抓手，同时配备重症风险预测模型与辅助决策等智能应用系统，为完善国家重症临床中心平台体系建设，建立国家重症专病数据标准，打造大规模的重症多中心协创网络奠定良好的基础。

YiduCloud will prioritize the construction of a sepsis specialty database and complement it with intelligent applications such as an intensive care risk prediction model and decision support systems. This initiative aims to improve the national critical care center platform, establish national standards for critical illness specialty data, and lay a solid foundation for the development of a large-scale collaborative network for critical care across multiple centers.

医渡云中标西南地区某三甲医院眼科专科库采购项目

YiduCloud has won the bid for the procurement contract of the Ophthalmology Specialty Database in a prestigious Grade A tertiary hospital in the Southwest region

医渡云将基于先进的 AI 和大数据技术，对该院优势学科-眼科进行试点建设，覆盖科室 5-6 种常见疾病（白内障、青光眼、视光、角膜眼底、葡萄膜炎、眼底），提供数据分析、数据搜索、患者科研视图、疾病重点事件时间轴、一站式全流程科研管理、患者随访等智能化应用，进而支撑建立专项的科研课题进行回顾性和前瞻性的科研分析，进行药品临床试验和药品评价研究，助力提升医院的科研能力。

Based on advanced AI and big data technologies, YiduCloud will pilot the construction of the ophthalmology department, which is one of the hospital's advantageous disciplines. It will cover five to six common diseases within the department, including cataracts, glaucoma, optometry, cornea and fundus, uveitis, and retinal diseases. YiduCloud will provide intelligent applications such as data analysis, data search, patient research views, disease event timelines, comprehensive research management, and patient follow-up. These applications will support the establishment of specialized research projects for retrospective and prospective research analysis, clinical drug trials, and drug evaluation studies, thereby enhancing the hospital's research capabilities.

集团荣誉

Group Honors


医渡科技旗下医渡云荣获华为中国合作伙伴大会“优秀解决方案奖”

YiduCloud, a subsidiary of Yidu Tech, was awarded the prestigious "Excellent Solution Award" at the Huawei China Partner Conference

以“因聚而生 众志成城”为主题的“华为中国合作伙伴大会 2023”在深圳举办。医渡科技旗下医渡云作为华为重要合作伙伴受邀出席。凭借在医疗人工智能领域突出

的技术实力和创新能力，医渡云“传染病智慧化监测预警解决方案”荣获“优秀解决方案奖”，本次获奖不仅是对公司持续深耕医疗卫生领域的肯定，也标志着医渡云业务应用与华为技术生态的深度融合。

The Huawei China Partner Conference 2023 was held in Shenzhen with the theme of "Gathering and Achieving Public Ambition." YiduCloud, a subsidiary of Yidu Tech, was invited to attend as an important partner of Huawei. With outstanding technological strength and innovation capabilities in the field of healthcare artificial intelligence, YiduCloud's "Intelligent Monitoring and Early Warning Solution for Infectious Diseases" has been awarded the "Excellent Solution Award." This award not only recognizes the company's continuous efforts in the healthcare sector but also signifies the deep integration of YiduCloud's business applications with Huawei's technological ecosystem.



投资者交流

Investor Communication

中金公司首次覆盖医渡科技并给予“跑赢行业”评级

China International Capital Corporation has initiated coverage on Yidu Tech and assigned it an "Outperform" rating

中金公司发布研报，首次覆盖医渡科技并给予“跑赢行业”评级。中金公司看好医渡科技通过成熟的大数据平台业务所积累起的行业洞察和客户资源，并认为医渡科技有望持续开拓多元的变现空间。

China International Capital Corporation (CICC) has released a research report, providing coverage for Yidu Tech for the first time and giving it an "Outperform" rating. CICC is optimistic about Yidu Tech's industry insights and customer resources accumulated through its mature big data platform business. They believe that Yidu Tech has the potential to continuously explore diverse monetization opportunities.

国金证券发布研究报告提及医渡科技

Research report issued by Sinolink Securities mentions Yidu Tech

国金证券发布研究报告称，近年来，国内医药健康企业积极布局人工智能领域应用，取得诸多进展，提到医渡科技通过使用符号认知推理模型及深度学习等 AI 技术不断迭代真实世界疾病模型，持续深化对疾病的洞见，在血液病领域与两家国家血液系统疾病临床医学研究中心医院合作共建血液系统疾病研究网络，建立了多个重大血液系统疾病专病库和大型临床研究队列，并且为政府提供 AI 赋能的数据分析驱动型解决方案，从而优化公共卫生治理水平。

Sinolink Securities has released a research report highlighting the active expansion and significant progress of domestic pharmaceutical and healthcare companies in the field of artificial intelligence in recent years. The report specifically mentions Yidu Tech's utilization of symbol cognitive reasoning models, deep learning, and other AI technologies to continuously enhance real-world disease models and gain deeper insights into diseases. In the field of hematology, Yidu Tech has partnered with two national clinical research centers for blood system diseases, establishing a research network, multiple specialized disease databases, and large-scale clinical research



cohorts. Additionally, Yidu Tech offers AI-driven data analysis solutions to government entities, contributing to the optimization of public health governance.